Cisen Pharmaceutical News

Chenxin Pharmaceutical (603367): Benefiting from medical recovery and new product development, the company is expected to develop steadily

國投證券Apr 29 11:00

Chenxin Pharmaceutical (603367) Third Quarterly Report Review: Accelerated Performance Growth Exceeds Expectations, Continued Increase in Profitability

西南證券Oct 25, 2018 11:00

Chen Xin Pharmaceutical (603367) Interim Report: Performance continues to grow at a high level, and all product lines perform well

西南證券Aug 22, 2018 11:00

Chen Xin Pharmaceutical Industry (603367) Quarterly report comments: annual results may continue to exceed expectations of large infusion industry reversal

西南證券Apr 26, 2018 11:00

Chen Xin Pharmaceutical Industry (603367) dynamic follow-up report: Q1 forecast much higher than expected volume and price rise performance high growth

西南證券Apr 10, 2018 11:00

Chen Xin Pharmaceutical (603367) Annual report comments: high performance growth is expected to continue to exceed expectations in innovative drug research and development

西南證券Mar 28, 2018 11:00

Special report of Chen Xin Pharmaceutical Industry (603367): great room for innovative drugs to improve long-term performance

西南證券Mar 19, 2018 11:00

Chen Xin Pharmaceutical Industry (603367) Research report: the volume of specialized drugs plus the price increase of low-priced drugs promote high performance growth.

西南證券Mar 15, 2018 11:00

Research report on New shares of Chen Xin Pharmaceutical Industry (603367): a leading company in domestic infusion industry

興業證券Sep 17, 2017 11:00

Chen Xin Pharmaceutical Co., Ltd. (603367) IPO inquiry report

華鑫證券Sep 12, 2017 11:00